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Background: The T cell antigen receptors (TCR) of αβ and γδ T lymphocytes are believed to assemble in a similar
fashion in humans. Firstly, αβ or γδ TCR chains incorporate a CD3δε dimer, then a CD3γε dimer and finally a ζζ
homodimer, resulting in TCR complexes with the same CD3 dimer stoichiometry. Partial reduction in the expression
of the highly homologous CD3γ and CD3δ proteins would thus be expected to have a similar impact in the
assembly and surface expression of both TCR isotypes. To test this hypothesis, we compared the surface TCR
expression of primary αβ and γδ T cells from healthy donors carrying a single null or leaky mutation in CD3G (γ+/−)
or CD3D (δ+/−, δ+/leaky) with that of normal controls.
Results: Although the partial reduction in the intracellular availability of CD3γ or CD3δ proteins was comparable as
a consequence of the mutations, surface TCR expression measured with anti-CD3ε antibodies was significantly
more decreased in γδ than in αβ T lymphocytes in CD3γ+/− individuals, whereas CD3δ+/− and CD3δ+/leaky donors
showed a similar decrease of surface TCR in both T cell lineages. Therefore, surface γδ TCR expression was more
dependent on available CD3γ than surface αβ TCR expression.
Conclusions: The results support the existence of differential structural constraints in the two human TCR isotypes
regarding the incorporation of CD3γε and CD3δε dimers, as revealed by their discordant surface expression
behaviour when confronted with reduced amounts of CD3γ, but not of the homologous CD3δ chain. A modified
version of the prevailing TCR assembly model is proposed to accommodate these new data.
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The human T cell antigen receptors (TCR) of αβ and γδ
T lymphocytes are believed to assemble in a similar
fashion [1]. First, variable αβ or γδ heterodimers
bind to invariant CD3δε heterodimers, then to CD3γε
heterodimers and finally to CD247 (or TCRζ) homodimers,
resulting in surface TCR complexes with equal amounts of
the two different, albeit highly homologous, CD3
heterodimers. In contrast, mouse αβ and γδ TCR differ* Correspondence: regueiro@med.ucm.es
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distribution, and reproduction in any mediumdrastically in their stoichiometry, since the γδ TCR does
not incorporate any CD3δε dimers but, rather, two CD3γε
dimers [2]. This finding begs the question as to whether the
human variable αβ and γδ chains show identical affinity for
both CD3 heterodimers.
We reasoned that, if both the αβ and the γδ TCR
isotypes use identical amounts of CD3γε and CD3δε,
then decreased availability of CD3γ or CD3δ proteins, as
observed in heterozygous carriers of mutations in CD3
genes [3], would be expected to have a similar impact on
the assembly and surface expression of both αβ and γδ
TCR isotypes. To test this hypothesis, we compared
TCR surface levels of primary αβ and γδ T cells from
healthy haploinsufficient donors carrying null or leakyntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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results did not support the hypothesis of a similar im-
pact on both TCR isotypes, but rather suggested a differ-
ential CD3γε and CD3δε usage scheme for each TCR
isotype.
Results
Reduced surface αβ and γδ TCR expression in CD3γ+/−,
CD3δ+/− or CD3δ+/leaky human T lymphocytes
CD3G (γ+/−) or CD3D (δ+/−) haploinsufficient donors were
uniformly healthy and showed abundant peripheral blood
T lymphocytes with an essentially normal phenotype
(Table 1). However, total T cell numbers were consistently
lower than controls (Figure 1A) which correlated with a
partial impairment of lymphocyte function (Table 1).
We have previously observed in γ−/− individuals that
CD3 expression levels are overestimated when T cells
are defined using antibodies against TCR-associated
epitopes [7], such as BMA031 (for TCRαβ) or Immu510
(for TCRγδ). To avoid a similar bias in haploinsufficient
donors, TCR-independent electronic gates were firstTable 1 Lymphocyte studies in haploinsufficient individualsa
CD3 GENOTYPE γ+/−
Number of subjects 4
Ages 46 ± 10
LYMPHOCYTE IMMUNOPHENOTYPE (%)
T (CD3+) 60 ± 6
T (CD3+CD4+) 45 ± 4
T (CD3+CD8+) 18 ± 1
B (CD19+) 18 ± 5
NK (CD3−CD16+/CD56+) 17 ± 3
LYMPHOCYTE FUNCTION
T cell proliferation (% of control max)b
Medium 3 ± 1
Anti-CD3 (UCHT-1) 74 ± 4
Phytohemagglutinin (PHA) 61 ± 5
Serum Ig (mg/dl)
IgG 790 ± 319
IgA 306 ± 54
IgM 47 ± 29
IgG1 611 ± 37
IgG2 165 ± 222
IgG3 30 ± 6
IgG4 9 ± 6
NK cell cytotoxicity (% lysis) 52 ± 6
aMean ± SD of the indicated number of different subjects. When available, multiple
Data obtained from several sources, including published material [4,5].
bPercentage proliferation (H3-thymidine uptake for γ+/− and δ+/−donors, CFSE dilutio
in each experiment.defined in order to identify αβ or γδ T cell subsets
(Figure 1B). The results indicated that CD3+ cells within
CD4+ or CD8bright lymphocytes were >98% αβ T cells,
whereas CD3+ double negative (DN) lymphocytes were
78 ± 6% γδ T cells. Accordingly, αβ and γδ T cells were
gated as CD4+/CD8bright and DN cells, respectively, for
further analyses. Using several CD3-specific antibodies,
analysis of surface TCR expression consistently
showed reduced antibody binding in γ+/− and δ+/− T
lymphocytes as compared to normal controls (50-90% as
judged by their relative mean fluorescence intensity,
Figure 2A, B). These results were confirmed in family
members of two newly reported patients with a leaky
mutation in CD3D (termed δ+/leaky) [8]. Consistent with
their relatively higher CD3δ content as compared to δ+/−
donors, δ+/leaky donors showed a milder, but nevertheless
clear decrease in surface TCR expression (Figure 2A, B).
In order to establish if these results were associated with
reduced availability of each CD3 chain, we measured
intracellular CD3γ (iCD3γ) or CD3δ (iCD3δ) by flow
cytometry in haploinsufficient γ+/− and δ+/leaky donors.δ+/− δ+/leaky Normal adults
2 2 12
44 33 ± 1 37 ± 12
Mean (range)
66 ± 1 62 ± 5 71 (54–77)
39 ± 5 26 ± 1 43 (30–53)
26 ± 6 16 ± 7 32 (16–39)
12 ± 2 ND 12 (6–19)
17 ± 2 9 ± 6 15 (8–31)
Normal control
1 8 ± 2 4 ± 3
ND 84 ± 6 100
60 ± 4 ND 100








80 ± 5 ND 31 (21–41)
values from single donors were included as single means in the calculations.
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Figure 1 Peripheral αβ and γδ T lymphocyte numbers in human CD3G or CD3D haploinsufficiencies. (A) Peripheral blood cell counts from
different γ+/−, δ+/− or δ+/leaky individuals are compared with the normal age-matched distribution as mean ± SEM against the P5/P95 normal
range (horizontal dashed lines [6]). Asterisks in bars indicate significant differences as compared with controls. p < *0.05, **0.01 or ***0.001.
(B) Proportion of αβ (BMA031+) and γδ (Immu510+) T cells (defined as CD3+) in different peripheral blood subsets (CD4+, CD8bright, CD8dull and
DN) in healthy individuals. Data are mean ± SD (n = 6).
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(Figure 2C), confirming previous reports of decreased
CD3γ protein in haploinsufficient donors [3].
Serial dilutions of CD3 mAb further confirmed the
findings above (Figure 2D), since the reduced binding to
γ+/− T cells persisted in saturation conditions, but it was
gradually lost near the endpoint, supporting the exist-
ence of less CD3 binding sites [9].
From these results we conclude that human CD3G or
D haploinsufficient donors show reduced binding of
CD3-specific mAb to the TCR of their γδ and αβ T cells.
Discordant reduction of surface αβ and γδ TCR expression
in CD3γ+/− but not CD3δ+/− or CD3δ+/leaky human
T lymphocytes
Analysis of CD3 mAb surface binding to αβ and γδ T
cells with the different CD3G and CD3D genotypes, rela-
tive to normal controls, revealed that binding of CD3
mAb to γ+/− γδ T cells was unexpectedly poor (55 ± 3%)
as compared with γ+/− αβ T cells (82 ± 8%, Figure 2A).This discordant reduction was specific for γ+/− donors,
as it was not observed in δ+/− or δ+/leaky donors. Further
support for this discordant reduction was provided by
the γδ versus αβ CD3 expression ratio, which is normally
1.9 ± 0.22 [10,11] but becomes significantly less in γ+/−
donors only (Figure 3). Taken together, these results
indicate that normal surface γδ TCR expression in
humans is more critically dependent on the relative
availability of CD3γ, but not CD3δ, than that of the
αβ TCR.
Discussion
Human and mouse TCR complexes are assembled into
octamers following common cues provided by trans-
membrane ionizable aminoacids in each dimer, with
CD3γε and CD3δε ectodomains contributing additional
extracellular interactions for their ordered incorporation
into the complex [12]. The extracellular interactions are
quite specific, as the mouse γδ TCR does not incorpor-
ate otherwise available CD3δε dimers, but rather two
Figure 2 Reduced surface αβ and γδ TCR expression in CD3γ+/−, CD3δ+/− and CD3δ+/leaky individuals using UCHT-1. αβ T cells were
defined as CD8bright and CD4+ in 9 γ +/−, 4 δ+/−, 2 δ+/leaky and 7 +/+ donors. Similar results were obtained with other anti-CD3 mAb (SK7, S4.1,
F101.01, data not shown). (A) CD3 MFI ratios (X100) ± SEM relative to controls are shown for the indicated T cell lineages and genotypes. Asterisks
in bars indicate significant differences as compared with controls, other comparisons as indicated. p as in Figure 1A. (B) Representative peripheral
blood CD3 reactivity patterns of γ+/−, δ+/− or δ+/leaky T cells (dashed lines) as compared with +/+ controls (solid lines). The vertical line in each
panel indicates the upper limit of background fluorescence using isotype-matched irrelevant mAb. (C) Intracellular stainings of γ+/− and δ+/leaky T
cells (dashed lines) as compared with +/+ controls (solid lines). Vertical lines as in Figure 2B. The numbers in each histogram indicate MFI ratios
(x100) relative to controls. (D) Comparative titration of CD3 (UCHT1) binding (MFI) to γ+/− peripheral blood T cells (n = 1) versus +/+ controls
(n = 2, mean ± SD). The percentage of bound cells was determined in parallel to establish the endpoint dilution (1:16.000). The arrow indicates
the working dilution in all other experiments. Similar results were obtained using other antibodies (F101.01 or BMA031).
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contrast, the human γδ TCR incorporates both [2].
Mammalian CD3γ, but not CD3δ, has a uniquely kinked
ectodomain which fits into an asymmetrical loop in
TCRβ for optimal αβ TCR assembly and expression, and
cannot be easily replaced by CD3δ due to steric hin-
drance, with functional consequences [13]. This likely
leads to the conserved structural asymmetry shared by
the human and mouse αβ TCR. In contrast, TCRγ lacks
the asymmetrical loop of its TCRβ homologue and
seems to allow a less stringent (i.e., with less affinity)CD3 dimer usage in the γδ TCR, which may explain its
disparate stoichiometry in the two species.
The present study suggests that there must be differ-
ential structural constraints for the building and stable
expression of αβ and γδ TCR complexes, as revealed by
their discordant behaviour in cell surface expression
when confronted with reduced availability of CD3γ, but
not of CD3δ (Figures 2 and 3). Our findings are in
agreement with available information about the assembly
of human surface αβ and γδ TCR [12], as explained
above and as proposed in Figure 4. In the model, CD3δε
CD3 genotype






















Figure 3 Discordant reduction of surface αβ and γδ TCR
expression in CD3γ+/− vs CD3δ+/− or CD3δ+/leaky individuals.
CD3 MFI ratios ± SEM of γδ versus αβ T cells for the indicated
genotypes using UCHT-1. * indicates p < 0.05 as compared with
other donors.
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TCRδ chains (step 1), thus reduced CD3δ expression
has a similar impact on both. In contrast, when CD3γ is
limiting, lack of a CD3γε-fitting structure in TCRγ, as
opposed to TCRβ [13], may result in a lower affinity of
the former relative to the latter for CD3γε. This may
favour the incorporation of competing CD3δε dimers to
nascent γδ TCR complexes (step 2), and wouldγ
γ
β




Figure 4 Simplified model for the effect of human CD3
haploinsufficiencies on TCR assembly and expression. Lack of a
CD3γε-fitting structure in TCRγ, as opposed to TCRβ [13] (shown in
black), and the resultant lower affinity of the former relative to the
latter for the CD3γε dimer (represented by arrows), may explain the
stronger impact of decreasing CD3γ (shown with a nick) but not
CD3δ availability on surface γδ TCR expression as compared to that
of the αβ TCR.ultimately lead to γδ TCR receptors devoid of the
required stability for optimal surface expression. More-
over, human TCRδ (but not TCRα) can stably recruit
not only CD3δε but also CD3γε [14] during step1, which
may reduce further the availability of CD3γε dimers for
step2 when CD3γ is limiting (not shown).
Further studies are required to demonstrate a direct
link between CD3γ or δ availability and TCR assembly
and surface expression. However, the paucity of CD3
haploinsufficient individuals might hamper these studies
in humans. A flow cytometry-based approach as
illustrated in Figure 2B could help to identify such
individuals.
Lastly, since carriers of CD3G or CD3D mutations
showed affected TCR expression (Figure 2) and T-cell
selection (Figure 1), which seemed in turn to impair to
some extent T-cell function (Table 1) [15] the question
of whether they also have increased risk of immuno-
logical dysfunction deserves further investigation.
Conclusions
The results indicate that the dimer assembly scheme of
the human TCR complex is different in αβ versus γδ T
cells, as revealed by their discordant behaviour when
confronted with limiting amounts of CD3γ, but not of
the homologous CD3δ chain. The novel data allow




After obtaining informed consent following IRB
authorization (Ethics Committee for Clinical Investiga-
tion of Clínico San Carlos Hospital, Madrid), we studied
nine healthy heterozygous carriers of mutations in CD3γ
(γ+/−) [3,7] of Spanish or Turkish descent and six healthy
heterozygous carriers of mutations in CD3δ (δ+/−,
δ+/leaky) [8,16,17] of Japanese, Mennonite or Colombian
descent. Normal donors (termed+/+) were used as
controls. Their lymphocyte immunophenotype and func-
tional features are summarized in Table 1. PBL were
isolated by Ficoll-Hypaque (GE Healthcare) gradients
and resuspended in RPMI 1640 medium (Gibco)
supplemented with 10% FCS (PAA Laboratories), 1% L-
glutamine and antibiotics-antymitotic (100 units/ml of
penicillin G, 100 μg/ml of streptomycin sulfate, and
0.25 μg/ml of amphotericin B) from Gibco.
Antibodies and flow cytometry
The expression of different surface markers was studied
by flow cytometry using standard procedures in fresh
whole blood or isolated PBL [18]. For intracellular
stainings cells were fixed and permeabilized as previ-
ously reported [19].
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(S4.1) from Caltag Laboratories (now Invitrogen),
anti-CD3εγ/εδ (UCHT-1), anti-TCR αβ (BMA031),
and anti-TCRγδ (Immu510) from Beckman Coulter,
anti-CD3ε (SK7), anti-CD4 (Leu2a), anti-CD8 (Leu3a),
anti-TCRγδ (11F2), and anti-CD8 (SK1) from BD
Biosciences. Anti-CD3εγ/εδ (F101.01) hybridoma super-
natant and anti-CD3δ (APA1/2) ascitic fluid were a gen-
erous gift from Dr. B. Rubin (CHU de Purpan, France).
TG5 (an anti-CD3γ rabbit antiserum raised against the
CD3γ C-terminal peptide GLQGNQLRRN) was kindly
provided by D. Alexander (Babraham Institute, U.K.).
The mAb were FITC-, PE-Cy5 or PE-conjugated, or
purified, and for the latter a PE-conjugated goat anti-
mouse IgG (H + L) or anti-rabbit (H + L) from Caltag
Laboratories was used as a secondary reagent. Back-
ground fluorescence was defined with an isotype-
matched irrelevant mAb from Caltag Laboratories. For
comparative stainings we used the mean fluorescence in-
tensity (MFI), defined as the average fluorescence value
of the corresponding mAb referred to the logarithmic
scale of fluorescence intensity along the x-axis of the
histograms. Data were analyzed with FlowJo software
(TreeStar).
Proliferative assays
1×105 PBLs were placed in round-bottom microtitre
wells and stimulated with 10 μg/ml anti-human CD3
(UCHT-1) or 10 μg/ml PHA. After 3 days of in vitro
culture, wells were individually pulsed with 1 μCi of
3H-TdR (Amersham, Buckinghamshire, U.K.) for an-
other 16 to 18 h and harvested onto glass fiber
filters. Thymidine incorporation into cellular DNA
was evaluated as cpm in a scintillation βcounter
(Packard, Meriden, CT).
For CFSE (carboxyfluorescein diacetate succinimidyl
ester) dilution experiments, cells were labeled with 1 μM
CFSE in PBS for 10 min at 37°C at day 0, washed twice
in cold PBS, plated and stimulated as above. CFSE dilu-
tion was subsequently determined by flow cytometry
within CD3+ lymphocytes.
Cytotoxicity assays
Cytotoxicity was measured using the nonradioactive
Cytotoxicity Detection kit LDH (Roche). Cells were
cocultured in a 96 V-well plates for 4 h at 25: 1 (Effector:
Target) ratios and the percentage of specific lysis was
determined from the amount of lactate dehydrogenase ac-
tivity detected in culture supernatants.
Statistical analysis
Student’s t-tests were performed using SPSS 11.5.1 stat-
istical program software (Chicago, IL). Only p values
below 0.05 were considered significant. Data arepresented as mean ± SEM (standard error of the mean)
or ± SD (standard deviation).
Abbreviations
PBL: Peripheral blood lymphocytes; MFI: Mean flourescence intensity; TCR:
T cell antigen receptor; FCS: Fetal calf serum; ND: Not done; NS: Not
significant.
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